2. Narayan P. Tunuguntla HSGR. Long-term efficacy and safety of tamsulosin for benign prostatic hyperplasia. Rev Urol. 2005;7 Suppl 4:S42–48. http://www.ncbi.nlm.nih.gov/pubmed/16986054

3. Vickman R.E., Franco O.E., Moline D.C., Vander Griend D.J., Thumbikat P., Hayward S.W. The role of the androgen receptor in prostate development and benign prostatic hyperplasia: A review. Asian J Urol. 2020;7(3):191– 202. Doi: 10.1016/j.ajur.2019.10.003.

4. Nimeh T., Magnan B., Almallah Y. Benign Prostatic Hyperplasia: Review of Modern Minimally Invasive Surgical Treatments. Semin Intervent Radiol. 2016;33(03):244–250. Doi: 10.1055/s-0036-1586148.

5. Abrams P., Kelleher C.J., Kerr L.A., Rogers R.G. Overactive bladder significantly affects quality of life. Am J Manag Care. 2000;6(11 Suppl):S580–590. http://www.ncbi.nlm.nih.gov/pubmed/11183901

6. Dugan E., Cohen S.J., Bland D.R., ,Preisser J.S., Davis C.C.,Suggs P.K., McGann P. The Association of Depressive Symptoms and Urinary Incontinence Among Older Adults. J Am Geriatr Soc. 2000;48(4):413– 416. Doi: 10.1111/j.1532-5415.2000.tb04699.x.

7. Bachmann A., Descazeaud A., Emberton M., Gravas S., Michel M.C. Nordling J. EAU: Guidelines on Male Lower Urinary Tract Symptoms ( LUTS ), including Benign Prostatic Obstruction ( BPO ). Eur Assoc Urol. 2015;(February):123–144. Doi: 10.1016/j.eururo.2013.03.004.

8. Michel M., Kenny B., Schwinn D. Classification of a1-adrenoceptor subtypes. Naunyn Schmiedebergs Arch Pharmacol. 1995;352(1). Doi: 10.1007/BF00169183.

9. Yarovoy S.K. Silodosin is a new drug of selective group. Experimental and Clinical Urology. 2012;3:57–62. Russian (Яровой С.К. Силодозин – новый препарат группы селективных. Экспериментальная и клиническая уролога. 2012;3:57–62).

10. Novara G., Tubaro A., Sanseverino R., Spatafora S., Artibani W., Zattoni F., Montorsi F., Chapple C.R. Systematic review and meta-analysis of randomized controlled trials evaluating silodosin in the treatment of non-neurogenic male lower urinary tract symptoms suggestive of benign prostatic enlargement. World J Urol. 2013;31(4):997–1008. Doi: 10.1007/ s00345-012-0944-8.

11. Roehrborn C.G. Efficacy of alpha-Adrenergic Receptor Blockers in the Treatment of Male Lower Urinary Tract Symptoms. Rev Urol. 2009;11(Suppl 1):S1–58. http://www.ncbi.nlm.nih.gov/ pubmed/20126606

12. Martov A.G., Ergakov D.V. Therapy of lower urinary tract symptoms caused by benign prostatic hyperplasia: what is new in 2016. Effective pharmacotherapy 2016;(353):6–12. Russian (Мартов А.Г., Ергаков Д.В. Терапия симптомов нижних мочевых путей, обусловленных доброкачественной гиперплазией предстательной железы: что нового в 2016 году. Эффективная фармакотерапия 2016;(353):6–12).

13. Sychev D.A. Recommendations on the use of pharmacogenetic testing in clinical practice. Quality Clinical Practice. 2011;(1):3-10. Russian (Сычёв Д.А. Рекомендации по применению фармакогенетического тестирования в клинической практике. Качественная Клиническая Практика. 2011;(1):3–10).

14. Ahmad T., Valentovic M.A., Rankin G.O. Effects of cytochrome P450 single nucleotide polymorphisms on methadone metabolism and pharmacodynamics. Biochem Pharmacol. 2018;153:196–204. Doi: 10.1016/j.bcp.2018.02.020.

15. Lindh J.D., Holm L., Andersson M.L., Rane A. Influence of CYP2C9 genotype on warfarin dose requirements-a systematic review and meta-analysis. Eur J Clin Pharmacol. 2009;65(4):365–375. Doi: 10.1007/ s00228-008-0584-5.

16. Paré G., Mehta S.R., Yusuf S., Anand S.S., Connolly S.J., Hirsh J., Simonsen K., Bhatt D.L., Fox K.A.A., Eikelboom J.W. Effects of CYP2C19 Genotype on Outcomes of Clopidogrel Treatment. N Engl J Med. 2010;363(18):1704–1714. Doi: 10.1056/NEJMoa1008410.

17. The SEARCH Collaborative Group. SLCO1B1 Variants and Statin-Induced Myopathy – A Genomewide Study. N Engl J Med. 2008;359(8):789–799. Doi: 10.1056/NEJMoa0801936.

18. Blake C.M., Kharasch E.D., Schwab M., Nagele P. A Meta-Analysis of CYP2D6 Metabolizer Phenotype and Metoprolol Pharmacokinetics. Clin Pharmacol Ther. 2013;94(3):394–399. Doi: 10.1038/clpt.2013.96.

19. Waade R.B., Solhaug V., Høiseth G. Impact of CYP2D6 on serum concentrations of flupentixol, haloperidol, perphenazine and zuclopenthixol. Br J Clin Pharmacol. 2021;87(5):2228-2235. Doi: 10.1111/bcp.14626.

20. Kim K.-A., Park I.-B., Park J.-Y. Effects of CYP2D6 and CYP3A5 genetic polymorphisms on steady-state pharmacokinetics and hemodynamic effects of tamsulosin in humans. Eur J Clin Pharmacol. 2018;74(10):1281– 1289. Doi: 10.1007/s00228-018-2501-x.

21. Van Hoogdalem E.J., Soeishi Y., Matsushima H., Higuchi S. Disposition of the Selective α1A-Adrenoceptor Antagonist Tamsulosin in Humans: Comparison with Data from Interspecies Scaling. J Pharm Sci. 1997;86(10):1156–1161. Doi: 10.1021/js960303k.

22. Lowe F.C. Summary of clinical experiences with tamsulosin for the treatment of benign prostatic hyperplasia. Rev Urol. 2005;7 Suppl 4:S13–21. http://www.ncbi.nlm.nih.gov/pubmed/16986050

23. Michel M.C., Korstanje C., Krauwinkel W. Cardiovascular Safety of Tamsulosin Modified Release in the Fasted and Fed State in Elderly Healthy Subjects. Eur Urol Suppl. 2005;4(2):9–14. Doi: 10.1016/j. eursup.2004.11.003.

24. Soeishi Y., Matsushima H., Watanabe T., Higuchi S., Cornelissen K., Ward J. Absorption, metabolism and excretion of tamsulosin hydrochloride in man. Xenobiotica. 1996;26(6):637–645. Doi: 10.3109/00498259609046739.

25. Kamimura H., Oishioe S., Matsushima H., Watanabe T., Higuchi S., Hall M., Wood S.G., Chasseaud L.F. Identification of cytochrome P450 isozymes involved in metabolism of the α1-adrenoceptor blocker tamsulosin in human liver microsomes. Xenobiotica. 1998;28(10):909– 922. Doi: 10.1080/004982598238985.

26. Bertz R.J., Granneman G.R. Use of In Vitro and In Vivo Data to Estimate the Likelihood of Metabolic Pharmacokinetic Interactions. Clin Pharmacokinet. 1997;32(3):210–258. Doi: 10.2165/00003088- 199732030-00004.

27. Guengerich F.P. Cytochromes P450, Drugs, and Diseases. Mol Interv. 2003;3(4):194–204. Doi: 10.1124/mi.3.4.194.

28. Thorn C.F., Klein T.E., Altman R.B. PharmGKB: The Pharmacogenetics and Pharmacogenomics Knowledge Base. In: Pharmacogenomics. Humana Press; :179-192. Doi: 10.1385/1-59259-957-5:179.

29. Park P-W., Seo Y.H., Ahn J.Y., Kim K-A., Park J-Y. Effect of CYP3A5*3 genotype on serum carbamazepine concentrations at steady-state in Korean epileptic patients. J Clin Pharm Ther. 2009;34(5):569–574. Doi: 10.1111/j.1365-2710.2009.01057.x.

30. Kuehl P., Zhang J., Lin Y., Lamba J., Assem M., Schuetz J., Watkins P.B. et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet. 2001;27(4):383–391 Doi: 10.1038/86882.

31. Zanger U.M., Raimundo S., Eichelbaum M. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol. 2004;369(1):23–37. Doi: 10.1007/ s00210-003-0832-2.

32. Crews K.R., Monte A.A., Huddart R., Caudle K.E., Kharasch E.D., Gaedigk A., Dunnenberger H.M. et al. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, OPRM1, and COMT Genotypes and Select Opioid Therapy. Clin Pharmacol Ther. 2021;110(4):888–896. Doi: 10.1002/cpt.2149.

33. FDA (1997). Flomax® (tamsulosin hydrochloride) capsules - Drug Label. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/ label/2019/020579s033lbl.pdf (Accessed 01/23/2019).

34. Choi C.-I., Bae J.-W., Jang C.-G., Lee S.-Y. Tamsulosin Exposure Is Significantly Increased by the CYP2D6*10/*10 Genotype. J Clin Pharmacol. 2012;52(12):1934-1938. Doi: 10.1177/0091270011432168.

35. Villapalos-García G., Zubiaur P., Navares-Gómez M., et al. Effects of Cytochrome P450 and Transporter Polymorphisms on the Bioavailability and Safety of Dutasteride and Tamsulosin. Front Pharmacol. 2021;12:718281. Doi: 10.3389/fphar.2021.718281.36.

36. Takata R., Matsuda K., Sugimura J., Obara W., Fujioka T., Okihara K., Takaha N. et al. Impact of four loci on serum tamsulosin hydrochloride concentration. J Hum Genet. 2013;58(1):21–26. Doi: 10.1038/ jhg.2012.126.

37. Bradford L.D. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics. 2002;3(2):229–243. Doi: 10.1517/14622416.3.2.229.